Abstracts tagged "longitudinal studies"

Abstract Number: 1389 • ACR Convergence 2022
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Patrick Garnero¹, Evelyne Gineyts¹, Jean-Charles Rousseau¹, Pascal Richette², Jérémie SELLAM³ and Roland Chapurlat¹, ¹INSERM 1033, Lyon, France, ²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 1459 • ACR Convergence 2022
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
Michelle Barraclough¹, Juan Pablo Diaz-Martinez², Andrea Knight³, Kathleen Bingham⁴, Jiandong Su², Mahta Kakvan⁵, Carolina Munoz², Maria Carmela Tartaglia⁶, Leslet Ruttan⁷, Joan Wither⁵, May Choi⁸, Nicole Anderson⁹, Dennisse Bonilla², Simone Appenzeller¹⁰, Ben Parker¹¹, Patricia Katz¹², Dorcas Beaton¹³, Robin Green⁷, Ian N. Bruce¹⁴ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁹Schroeder Arthritis Institute, Krembil Research Institute and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Unicamp, Campinas, São Paulo, Brazil, ¹¹Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ¹²UCSF, San Rafael, CA, ¹³Institute for Work & Health, Toronto, ON, Canada, ¹⁴Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Subjective cognitive impairment (SCI) is a significant problem in SLE and there are a lack of studies assessing change over time in SCI. The…
Abstract Number: 2197 • ACR Convergence 2022
Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US
Prajakta Masurkar¹, Jennifer Reckleff², Nicole Princic³, Brendan Limone⁴, Hana Schwartz⁴, Elaine Karis⁵, Eric Zollars⁶, Bradley Stolshek⁵ and Karen Costenbader⁷, ¹Amgen, Wylie, TX, ²Amgen, Westlake Village, CA, ³IBM Watson Health, Reading, MA, ⁴IBM Watson Health, Bethesda, MD, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen, Newbury Park, CA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Poor treatment adherence and persistence is an ongoing problem among SLE patients due to complex regimens and may lead to frequent use of high-dose…
Abstract Number: 1510 • ACR Convergence 2022
Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
Gareth Jones¹, Ovidiu Rotariu¹, Brigitte Michelsen², Bente Glintborg³, Bjorn Gudbjornsson⁴, Arni Geirsson⁵, Heikki Relas⁶, Pia Isomäki⁷, Jakub Závada⁸, Karel Pavelka⁹, Ziga Rotar¹⁰, Matija Tomsic¹⁰, Michael Nissen¹¹, Adrian Ciurea¹², Catalin Codreanu¹³, Johan Karlsson Wallman¹⁴, Eirik Kristianslund¹⁵, Simon Rasmussen¹⁶, Lykke Ørnbjerg¹⁷, Maria José Santos¹⁸, Mikkel Østergaard¹⁹, Merete L Hetland²⁰ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, Scotland, United Kingdom, ²Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Kristiansand, Norway, ³Rigshospitalet, Glostrup, Virum, Denmark, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁶Rheumatology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ⁷Centre for Rheumatology, Tampere University Hospital, Tampere, Finland, ⁸Institute of Rheumatology, Prague, Czech Republic, ⁹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹Hopitaux Universitaires de Genève, Geneva, Switzerland, ¹²University Hospital Zurich, Zürich, Switzerland, ¹³Center for Rheumatic Diseases, Bucharest, Romania, ¹⁴Lund University and Skane University Hospital, Hjarup, Sweden, ¹⁵Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ¹⁷Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹⁸Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ¹⁹Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ²⁰Rigshospitalet, Glostrup, Denmark
Background/Purpose: In axial spondyloarthritis (axSpA) much attention has been focused on pharmacological management, including tumour necrosis factor inhibitors (TNFi), as a means to reducing inflammation,…
Abstract Number: 0074 • ACR Convergence 2022
Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US
Prajakta Masurkar¹, Jennifer Reckleff², Nicole Princic³, Brendan Limone⁴, Hana Schwartz⁴, Elaine Karis⁵, Eric Zollars⁶, Bradley Stolshek⁵ and Karen Costenbader⁷, ¹Amgen, Wylie, TX, ²Amgen, Westlake Village, CA, ³IBM Watson Health, Reading, MA, ⁴IBM Watson Health, Bethesda, MD, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen, Newbury Park, CA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: SLE treatment is complex, with a wide variety of medications commonly prescribed. Limited evidence exists in the literature with respect to treatment patterns, HCRU…
Abstract Number: 1553 • ACR Convergence 2022
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Faustino Peron Filho¹, Andressa de Souza Moreira², Anna Larissa Janes² and Alexandre Wagner de Souza², ¹UNIFESP-EPM, Mogi das Cruzes, São Paulo, Brazil, ²UNIFESP-EPM, São Paulo, Brazil
Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are…
Abstract Number: 0138 • ACR Convergence 2022
Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
Joerg Henes¹, Jasmin B. Kuemmerle-Deschner², Tobias Krickau³, Tilmann Kallinich⁴, Frank Dressler⁵, Gerd Horneff⁶, Florian Meier⁷, Ivan Foeldvari⁸, Frank Weller-Heinemann⁹, Birgit Kortus-Goetze¹⁰, Markus Hufnagel¹¹, Juergen Rech¹², Prasad T. Oommen¹³, Julia Weber-Arden¹⁴ and Norbert Blank¹⁵, ¹Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ²Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ³Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁶Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁷Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ⁸Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁹Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ¹⁰Division of Nephrology, University of Marburg, Marburg, Germany, ¹¹Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹²University Clinic Erlangen, Erlangen, Germany, ¹³Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹⁴Novartis Pharma GmbH, Nuernberg, Germany, ¹⁵Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Familial Mediterranean fever (FMF) is a chronic disease characterized by recurrent episodes of fever and serositis, with a risk of severe complications (e. g.…
Abstract Number: 1575 • ACR Convergence 2022
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Larson⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of California Los Angeles, Los Angeles, CA, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵University of South Florida, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
Abstract Number: 0243 • ACR Convergence 2022
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka¹, Eisuke Inoue², Kotaro Watanabe³, Mai Abe³, Eri Sugano³, Kumiko Saka³, Moeko Ochiai³, Rei Yamaguchi³, Katsunori Ikari⁴ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Research Administration Center, Showa University, Shinagawa-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Japan, ⁴Department of Orthopedic Surgery, Tokyo Women’s Medial University School of Medicine, Shinjuku, Japan
Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…
Abstract Number: 1645 • ACR Convergence 2022
Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis
Mehreen Soomro¹, Michael Stadler¹, Sebastien Viatte¹, Alex Macgregor², Suzanne Verstappen¹, Anne Barton¹ and John Bowes¹, ¹The University of Manchester, Manchester, United Kingdom, ²The University of East Anglia, Norwich, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…
Abstract Number: 0309 • ACR Convergence 2022
Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study
Eugen Feist¹, Evgeny Nasonov², Michael Luggen³, Saeed Fatenejad⁴, Sergey Grishin⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³University of Cincinnati College of Medicine, Cincinnati, OH, ⁴SFC Medica, LLC, Charlotte, NC, ⁵R-Pharm, Moscow, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…
Abstract Number: 1668 • ACR Convergence 2022
Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
Alana Bruce¹, Alexander M Menzies², Georgina V Long², Brian Fernandes³ and Fredrick Joshua⁴, ¹Macquarie University, Balaclava, Victoria, Australia, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia, ⁴Macquarie University, Integrated Specialist Medical Care, Sydney, Australia
Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Tae-Han Lee¹, Bon San Koo², Bora Nam³, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim³, ¹Keimyung University Dongsan Hospital, Daegu, Republic of Korea, ²Inje University Seoul Paik Hospital, Seoul, Republic of Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay Von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Späthling-Mestekemper⁸, Christoph Kuhn⁹, Fabian Proft¹⁰, Denis Poddubnyy¹¹, Mathias Englbrecht¹² and Wolfgang Vorbrüggen¹³, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Rhein-Maas Klinikum, Wuerselen, Germany, ³Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁴Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁵Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ⁶rheumapraxis, Osnabrck, Germany, ⁷Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁸Rheumapraxis München, München, Germany, ⁹Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹²Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹³Verein zur Förderung der Rheumatologie e.V., Würselen, Germany
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].